GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zosano Pharma Corp (OTCPK:ZSANQ) » Definitions » PE Ratio

Zosano Pharma (Zosano Pharma) PE Ratio : At Loss (As of Apr. 29, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Zosano Pharma PE Ratio?

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-04-29), Zosano Pharma's share price is $0.0002. Zosano Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2022 was $-14.51. Therefore, Zosano Pharma's PE Ratio for today is At Loss.

Zosano Pharma's EPS (Diluted) for the three months ended in Mar. 2022 was $-7.86. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2022 was $-14.51.

As of today (2024-04-29), Zosano Pharma's share price is $0.0002. Zosano Pharma's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2022 was $-14.51. Therefore, Zosano Pharma's PE Ratio without NRI ratio for today is At Loss.

Zosano Pharma's EPS without NRI for the three months ended in Mar. 2022 was $-7.86. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2022 was $-14.51.

Zosano Pharma's EPS (Basic) for the three months ended in Mar. 2022 was $-7.86. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2022 was $-14.51.

Back to Basics: PE Ratio


Zosano Pharma PE Ratio Historical Data

The historical data trend for Zosano Pharma's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zosano Pharma PE Ratio Chart

Zosano Pharma Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Zosano Pharma Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Competitive Comparison of Zosano Pharma's PE Ratio

For the Biotechnology subindustry, Zosano Pharma's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zosano Pharma's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zosano Pharma's PE Ratio distribution charts can be found below:

* The bar in red indicates where Zosano Pharma's PE Ratio falls into.



Zosano Pharma PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Zosano Pharma's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=0.0002/-14.510
=-0(At Loss)

Zosano Pharma's Share Price of today is $0.0002.
Zosano Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-14.51.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Zosano Pharma  (OTCPK:ZSANQ) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


Zosano Pharma PE Ratio Related Terms

Thank you for viewing the detailed overview of Zosano Pharma's PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Zosano Pharma (Zosano Pharma) Business Description

Traded in Other Exchanges
N/A
Address
34790 Ardentech Court, Fremont, CA, USA, 94555
Zosano Pharma Corp is a clinical-stage biopharmaceutical company. It is focused on providing rapid systemic administration of therapeutics and other bioactive molecules to patients using the proprietary transdermal microneedle system. The system is designed to facilitate rapid drug absorption into the bloodstream, which can result in an improved pharmacokinetic profile compared to original dosage forms. The company's operating segment is to develop human pharmaceutical products. Its primary product candidate is Qtrypta (M207) which is the proprietary formulation of zolmitriptan delivered utilizing the system.
Executives
Christine Matthews officer: Chief Financial Officer C/O ZOSANO PHAMA CORPORATION, 34790 ARDENTECH COURT, FREMONT CA 94555
Steven Lo director, officer: Chief Executive Officer C/O CORCEPT THERAPEUTICS, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94010
Donald J Kellerman officer: VP, Clinical Dev & Med Affairs INSPIRE PHARMACEUTICALS, INC.,, 4222 EMPEROR BLVD., STE. 470, DURHAM NC 27703-8466
Elaine Yang director C/O ZOSANO PHARMA CORPORATION, 34790 ARDENTECH COURT, FREMONT CA 94555
Kenneth Greathouse director 3260 WHIPPIE ROAD, UNION CITY CA 94587
Hayley Lewis officer: See Remarks C/O CARBYLAN THERAPEUTICS, INC., 3181 PORTER DRIVE, PALO ALTO CA 94304
Kathy M. Mcgee director C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355
Linda S Grais director 86 ALEJANDRA AVE, ATHERTON CA 94027
Joseph P Hagan director 3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Kleanthis G Xanthopoulos director 9050 CAMINO SANTA FE, SAN DIEGO CA 92121
John Peter Walker director 126 ISABELLA AVE, ATHERTON CA 94027
Aisling Capital Partners Iv, Lp 10 percent owner 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Aisling Capital Partners Iv Llc 10 percent owner 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Aisling Capital Iv, Lp 10 percent owner 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Andrew N Schiff 10 percent owner PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022

Zosano Pharma (Zosano Pharma) Headlines

From GuruFocus

Zosano Pharma Files Voluntary Petition for Relief Under Chapter 11

By GuruFocusNews GuruFocusNews 06-02-2022

Zosano Pharma Announces Reverse Stock Split Effective Today

By GuruFocusNews GuruFocusNews 04-11-2022

Zosano Pharma Reports Second Quarter 2021 Financial Results

By Marketwired Marketwired 08-10-2021